Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Expanding Role of Data Science and Bioinformatics in Drug Discovery and Development.

Fingert HJ.

Clin Pharmacol Ther. 2018 Jan;103(1):47-49. doi: 10.1002/cpt.912. Epub 2017 Nov 14.

PMID:
29134636
2.

Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships.

Venkatakrishnan K, Zhou X, Ecsedy J, Mould DR, Liu H, Danaee H, Fingert H, Kleinfield R, Milton A.

J Clin Pharmacol. 2015 Mar;55(3):336-47. doi: 10.1002/jcph.410. Epub 2014 Nov 18.

PMID:
25302940
3.

An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes.

Goldberg SL, Fenaux P, Craig MD, Gyan E, Lister J, Kassis J, Pigneux A, Schiller GJ, Jung J, Jane Leonard E, Fingert H, Westervelt P.

Leuk Res Rep. 2014 Jul 5;3(2):58-61. doi: 10.1016/j.lrr.2014.06.003. eCollection 2014.

4.

Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study.

Falchook G, Kurzrock R, Gouw L, Hong D, McGregor KA, Zhou X, Shi H, Fingert H, Sharma S.

Invest New Drugs. 2014 Dec;32(6):1181-7. doi: 10.1007/s10637-014-0121-6. Epub 2014 Jun 1.

5.

Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.

Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH.

J Clin Oncol. 2014 Jan 1;32(1):44-50. doi: 10.1200/JCO.2012.46.8793. Epub 2013 Sep 16.

6.

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

Matulonis UA, Sharma S, Ghamande S, Gordon MS, Del Prete SA, Ray-Coquard I, Kutarska E, Liu H, Fingert H, Zhou X, Danaee H, Schilder RJ.

Gynecol Oncol. 2012 Oct;127(1):63-9. doi: 10.1016/j.ygyno.2012.06.040. Epub 2012 Jul 5.

PMID:
22772063
7.

Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations.

Dees EC, Cohen RB, von Mehren M, Stinchcombe TE, Liu H, Venkatakrishnan K, Manfredi M, Fingert H, Burris HA 3rd, Infante JR.

Clin Cancer Res. 2012 Sep 1;18(17):4775-84. doi: 10.1158/1078-0432.CCR-12-0589. Epub 2012 Jul 5.

8.

Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.

Cervantes A, Elez E, Roda D, Ecsedy J, Macarulla T, Venkatakrishnan K, Roselló S, Andreu J, Jung J, Sanchis-Garcia JM, Piera A, Blasco I, Maños L, Pérez-Fidalgo JA, Fingert H, Baselga J, Tabernero J.

Clin Cancer Res. 2012 Sep 1;18(17):4764-74. doi: 10.1158/1078-0432.CCR-12-0571. Epub 2012 Jul 2.

9.

Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.

Infante JR, Camidge DR, Mileshkin LR, Chen EX, Hicks RJ, Rischin D, Fingert H, Pierce KJ, Xu H, Roberts WG, Shreeve SM, Burris HA, Siu LL.

J Clin Oncol. 2012 May 1;30(13):1527-33. doi: 10.1200/JCO.2011.38.9346. Epub 2012 Mar 26.

PMID:
22454420
10.

Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics.

Macarulla T, Cervantes A, Elez E, Rodríguez-Braun E, Baselga J, Roselló S, Sala G, Blasco I, Danaee H, Lee Y, Ecsedy J, Shinde V, Chakravarty A, Bowman D, Liu H, Eton O, Fingert H, Tabernero J.

Mol Cancer Ther. 2010 Oct;9(10):2844-52. doi: 10.1158/1535-7163.MCT-10-0299. Epub 2010 Aug 19.

11.

Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors.

Dees EC, Infante JR, Cohen RB, O'Neil BH, Jones S, von Mehren M, Danaee H, Lee Y, Ecsedy J, Manfredi M, Galvin K, Stringer B, Liu H, Eton O, Fingert H, Burris H.

Cancer Chemother Pharmacol. 2011 Apr;67(4):945-54. doi: 10.1007/s00280-010-1377-y. Epub 2010 Jul 7.

12.

Assessing proarrhythmic potential of drugs when optimal studies are infeasible.

Rock EP, Finkle J, Fingert HJ, Booth BP, Garnett CE, Grant S, Justice RL, Kovacs RJ, Kowey PR, Rodriguez I, Sanhai WR, Strnadova C, Targum SL, Tsong Y, Uhl K, Stockbridge N.

Am Heart J. 2009 May;157(5):827-36, 836.e1. doi: 10.1016/j.ahj.2009.02.020. Review.

PMID:
19376308
13.

Brain natriuretic peptide: potential adjunct for cardiac risk assessment and management during treatment with experimental anticancer agents.

Varterasian ML, Meyer MB, Pressler ML, Fingert HJ, LoRusso PM.

AAPS J. 2007;9(2):E115-6. doi: 10.1208/aapsj0902012. No abstract available.

14.

Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development.

Curigliano G, Spitaleri G, Fingert HJ, de Braud F, Sessa C, Loh E, Cipolla C, De Pas T, Goldhirsch A, Shah R.

Eur J Cancer. 2008 Mar;44(4):494-500. Epub 2007 Nov 19. Review.

PMID:
18024014
15.

Cardiac safety, risk management, and oncology drug development.

Fingert HJ, Varterasian ML.

Clin Cancer Res. 2006 Jun 15;12(12):3646-7. No abstract available.

17.

Consideration of QT/QTc interval data in a phase I study in patients with advanced cancer.

Varterasian M, Fingert H, Agin M, Meyer M.

Clin Cancer Res. 2004 Sep 1;10(17):5967-8; author reply 5968-9. No abstract available.

18.

A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.

Tolcher AW, Kuhn J, Schwartz G, Patnaik A, Hammond LA, Thompson I, Fingert H, Bushnell D, Malik S, Kreisberg J, Izbicka E, Smetzer L, Rowinsky EK.

Clin Cancer Res. 2004 Aug 1;10(15):5048-57.

19.

Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961).

Panosyan EH, Grigoryan RS, Avramis IA, Seibel NL, Gaynon PS, Siegel SE, Fingert HJ, Avramis VI.

Anticancer Res. 2004 Mar-Apr;24(2C):1121-5.

20.

Baseline heart rate-corrected QT and eligibility for clinical trials in oncology.

Varterasian M, Meyer M, Fingert H, Radlowski D, Asbury P, Zhou X, Healey D.

J Clin Oncol. 2003 Sep 1;21(17):3378-9. No abstract available.

PMID:
12947082
21.

Antisense therapeutics in oncology: points to consider in their clinical evaluation.

Mani S, Gu Y, Wadler S, Fingert H.

Antisense Nucleic Acid Drug Dev. 1999 Dec;9(6):543-7.

PMID:
10645781
22.

Performance characteristics of a multimedia system for clinical data management.

Fingert HJ, Schneider DR.

Cancer Pract. 1994 May-Jun;2(3):194-201.

PMID:
8055023
23.

Cyclin E, a potential prognostic marker for breast cancer.

Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB.

Cancer Res. 1994 Jan 15;54(2):380-5.

24.

The fluorescent cytoprint assay in gynecological malignancies and breast cancer. Methodology and results.

Blackman KE, Fingert HJ, Fuller AF, Meitner PA.

Contrib Gynecol Obstet. 1994;19:53-63. Review. No abstract available.

PMID:
7995053
25.

Incapacitating autonomic neuropathy precipitated by taxol.

Jerian SM, Sarosy GA, Link CJ Jr, Fingert HJ, Reed E, Kohn EC.

Gynecol Oncol. 1993 Nov;51(2):277-80.

PMID:
7903950
26.
27.

Cisplatin, cytosine arabinoside, and pentoxifylline in the treatment of squamous cell carcinoma of the head and neck.

Stewart DJ, Cripps MC, Fingert H, Lamothe A, Laframboise G, Gerin-Lajoie J.

Am J Clin Oncol. 1993 Apr;16(2):123-6.

PMID:
8452103
28.

Predictive value of the fluorescent cytoprint assay (FCA): a retrospective correlation study of in vitro chemosensitivity and individual responses to chemotherapy.

Leone LA, Meitner PA, Myers TJ, Grace WR, Gajewski WH, Fingert HJ, Rotman B.

Cancer Invest. 1991;9(5):491-503.

PMID:
1933482
29.

Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up.

Thor AD, Schwartz LH, Koerner FC, Edgerton SM, Skates SJ, Yin S, McKenzie SJ, Panicali DL, Marks PJ, Fingert HJ, et al.

Cancer Res. 1989 Dec 15;49(24 Pt 1):7147-52.

30.

Implantation of human meningiomas into the subrenal capsule of the nude mouse. A model for studies of tumor growth.

Medhkour A, Van Roey M, Sobel RA, Fingert HJ, Lee J, Martuza RL.

J Neurosurg. 1989 Oct;71(4):545-50.

PMID:
2477514
31.

In vivo and in vitro enhanced antitumor effects by pentoxifylline in human cancer cells treated with thiotepa.

Fingert HJ, Pu AT, Chen ZY, Googe PB, Alley MC, Pardee AB.

Cancer Res. 1988 Aug 1;48(15):4375-81.

32.

Rapid growth of human cancer cells in a mouse model with fibrin clot subrenal capsule assay.

Fingert HJ, Chen Z, Mizrahi N, Gajewski WH, Bamberg MP, Kradin RL.

Cancer Res. 1987 Jul 15;47(14):3824-9.

33.
34.
35.

Enhanced lethality by methylxanthines in human bladder cancer cells treated with thiotepa.

Fingert HJ, Kindy RL, Pardee AB.

J Urol. 1984 Sep;132(3):609-13.

PMID:
6433047
36.

Megadose chemotherapy with bone marrow rescue.

Fingert HJ, Hochberg FH.

Prog Exp Tumor Res. 1984;28:67-78. No abstract available.

PMID:
6385130
37.

Cisplatin-vincristine-bleomycin therapy in squamous cell carcinoma of the head and neck.

Amrein PC, Fingert H, Weitzman SA.

J Clin Oncol. 1983 Jul;1(7):421-7.

PMID:
6199477
38.

Pancytopenia in mannosidosis.

Press OW, Fingert H, Lott IT, Dickersin CR.

Arch Intern Med. 1983 Jun;143(6):1266-8.

PMID:
6860058
39.

Psychoanalytic study of the minor prophet, Jonah.

FINGERT HH.

Psychoanal Rev. 1954 Jan;41(1):55-65. No abstract available.

PMID:
13121158
40.

Comments on the psychoanalytic significance of the fee.

FINGERT HH.

Bull Menninger Clin. 1952 May;16(3):98-104. No abstract available.

PMID:
14916300

Supplemental Content

Loading ...
Support Center